The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective.
The mitochondrial respiratory chain encephalomyopathies represent an important group of multisystem disorders. No curative treatment is currently available. A number of measures have been reported to have a theoretical potential to improve respiratory function. These treatment strategies have variable scientific support, many reports being anecdotal. We critically review the various therapeutic measures employed and suggest future treatment directions.
Walker
U A
UA
Melbourne Neuromuscular Research Centre, St. Vincent's Hospital Victoria, Australia.
Byrne
E
E
D016227:Benzoquinones / Q000627:therapeutic use*; D004272:DNA, Mitochondrial; D003999:Dichloroacetic Acid / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008931:Mitochondria, Muscle; D017237:Mitochondrial Encephalomyopathies / Q000150:complications* / Q000188:drug therapy* / Q000628:therapy*; D010085:Oxidative Phosphorylation; D026741:Physical Therapy Modalities; D012140:Respiratory Tract Diseases / Q000209:etiology*; D012256:Riboflavin / Q000627:therapeutic use*; D013831:Thiamine / Q000627:therapeutic use*; D014451:Ubiquinone / Q000627:therapeutic use*; D014812:Vitamin K / Q000627:therapeutic use*; D014815:Vitamins / Q000627:therapeutic use*
D016227:Benzoquinones; D004272:DNA, Mitochondrial; D007004:Hypoglycemic Agents; D014815:Vitamins; D014812:Vitamin K; D014451:Ubiquinone; D003999:Dichloroacetic Acid; D012256:Riboflavin; D013831:Thiamine